{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:50:46Z","timestamp":1761659446018,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arab Journal of Gastroenterology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ajg.2023.01.006","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T08:23:09Z","timestamp":1675066989000},"page":"104-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of glecaprevir\/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study"],"prefix":"10.1016","volume":"24","author":[{"given":"Byung Soo","family":"Kwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Min","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Goon","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil Jong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Dong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajg.2023.01.006_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ajg.2023.01.006_b0010","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jhep.2016.07.039","article-title":"Reversion of disease manifestations after HCV eradication","volume":"65","author":"van der Meer","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.ajg.2023.01.006_b0015","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ajg.2023.01.006_b0020","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ajg.2023.01.006_b0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ajg.2023.01.006_b0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ajg.2023.01.006_b0035","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guidelines Panel: Chair, EASL Governing Board representative, Panel members. EASL recommendations on treatment of hepatitis C: final update of the series\u2606. Journal of Hepatology. 2020;73(5):1170-218."},{"issue":"2","key":"10.1016\/j.ajg.2023.01.006_b0040","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for testing, managing, and treating Hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ajg.2023.01.006_b0045","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ajg.2023.01.006_b0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ajg.2023.01.006_b0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jvh.13038","article-title":"Glecaprevir\/pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2\/3 analysis","volume":"26","author":"Flamm","year":"2019","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.ajg.2023.01.006_b0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ajg.2023.01.006_b0065","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajg.2023.01.006_b0070","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.ajg.2023.01.006_b0075","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3350\/cmh.2018.1002","article-title":"Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD\/IDSA and 2016 EASL","volume":"24","author":"Yeon","year":"2018","journal-title":"Clin Mol Hepatol"},{"issue":"8","key":"10.1016\/j.ajg.2023.01.006_b0080","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jfma.2019.06.014","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in Asian patients with chronic hepatitis C","volume":"118","author":"Hsu","year":"2019","journal-title":"J Formos Med Assoc"},{"issue":"9","key":"10.1016\/j.ajg.2023.01.006_b0085","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","article-title":"Glecaprevir\u2013pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies\u2014a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)","volume":"5","author":"Wei","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.ajg.2023.01.006_b0090","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00535-019-01569-7","article-title":"Integrated analysis of 8-week glecaprevir\/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection","volume":"54","author":"Naganuma","year":"2019","journal-title":"J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ajg.2023.01.006_b0095","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.29557","article-title":"Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C","volume":"67","author":"Mauro","year":"2018","journal-title":"Hepatology"},{"issue":"10179","key":"10.1016\/j.ajg.2023.01.006_b0100","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ajg.2023.01.006_b0105","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy","volume":"71","author":"Mandorfer","year":"2020","journal-title":"Hepatology"}],"container-title":["Arab Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197923000060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687197923000060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:45:44Z","timestamp":1761659144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687197923000060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1687197923000060"],"URL":"https:\/\/doi.org\/10.1016\/j.ajg.2023.01.006","relation":{},"ISSN":["1687-1979"],"issn-type":[{"type":"print","value":"1687-1979"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of glecaprevir\/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Arab Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajg.2023.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}